Trump's week in review: Gaza peace deal push, Quantico speech

By Ryan Foley, Christian Post Reporter Saturday, October 04, 2025

4. FDA approves generic abortion drug

In a partially-redacted letter on Tuesday, the Food and Drug Administration informed Evita Solutions, LLC that it had approved its application to begin manufacturing and distributing its own version of Mifepristone tablets. Mifepristone is also known as the abortion pill. 

Evita Solutions, which now highlights the FDA's approval of its abortion pills on its website, describes its mission, in part, as to “normalize abortion care.” The FDA’s approval of Evita Solutions’ application comes four years after it was submitted on Oct. 1, 2021, at the beginning of the Biden administration. 

The Trump administration has largely sought to contrast itself with the Biden administration when it comes to abortion policy. The FDA’s approval of new abortion pills did not sit well with pro-life advocacy groups, which constitute an important part of the Trump coalition. 

“This reckless decision by the FDA to expand the availability of abortion drugs is unconscionable. These dangerous drugs take the lives of unborn children, place women and underage girls at serious risk, empower abusers, and trample the pro-life laws enacted by states across the nation,” said Susan B. Anthony Pro-Life America President Marjorie Dannenfelser in a statement condemning the development.

Dannenfelser called on the FDA to “at a minimum, immediately reinstate the commonsense safeguards that were in place during President Trump’s first term,” adding, “the Biden-era policy of removing doctors by allowing mail-order abortion drugs without in-person medical oversight must be reversed without delay.”

The FDA approval letter and Evita Solutions’ website both include links to information about the Risk Evaluation Mitigation Strategies, the “commonsense safeguards” that Dannenfelser was referring to. 

Secretary of Health and Human Services Robert F. Kennedy Jr., whose agency oversees the FDA, reacted to the backlash in a statement on X Thursday.

Kennedy insisted that a review of the safety of the abortion pill is ongoing and that the FDA “only approved a second generic mifepristone tablet because federal law requires approval when an application proves the generic is identical to the brand-name drug.”